Last reviewed · How we verify

Assessment of Safety and Immunogenicity of R21/Matrix-M™ in African Children Living With HIV

NCT05385510 PHASE1 COMPLETED

A Phase Ib trial to evaluate the safety and immunogenicity of R21/Matrix-M™ in African children living with HIV

Details

Lead sponsorUniversity of Oxford
PhasePHASE1
StatusCOMPLETED
Enrolment122
Start dateTue Jan 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
CompletionWed Sep 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Interventions

Countries

Uganda